Gadoxetate is strictly for use in a medical setting and is administered only by qualified healthcare professionals. You will not take this medication at home.

• Administration Method: It is given as a single intravenous (IV) injection into a vein, typically in your arm. The injection is usually performed as a slow bolus or infusion, generally at a rate of about 1 to 2 mL per second, as determined by the radiologist.
• Dosage Calculation: The dose of Gadoxetate is precisely calculated based on the patient’s body weight. The standard recommended dose for adults and pediatric patients (aged 2 months and older) is 0.025 mmol per kilogram (kg) of body weight, which is equivalent to 0.1 mL of Gadoxetate solution per kg (since the solution is 0.25 mmol/mL). This is a relatively lower dose compared to other GBCAs, due to its high relaxivity and liver uptake properties.
• Timing of Imaging: The imaging procedure involves multiple phases:
  • Dynamic Phase: Scanning begins immediately after injection (e.g., arterial phase at 15-25 seconds, porto-venous phase around 60 seconds, equilibrium phase around 120 seconds).
  • Hepatobiliary Phase (HBP): This is the crucial delayed phase, typically performed around 10 to 20 minutes after injection, and sometimes up to 120 minutes, to allow for optimal liver cell uptake.
• Post-Injection: After the Gadoxetate injection, a normal saline (salt water) flush is often given through the IV line to ensure complete delivery of the contrast agent and to clear the line.
• Monitoring: You will be closely monitored during and for a period after the injection for any immediate reactions.

You must follow any specific preparation instructions (e.g., fasting) given by your doctor or the imaging center for your MRI scan.

Gadoxetate works by altering the magnetic signals of water molecules in your body, which the MRI machine then detects to create images. It contains a gadolinium ion, which is a powerful “paramagnetic” substance. When Gadoxetate is injected into your vein, it rapidly distributes throughout the bloodstream and the extracellular fluid space, similar to other GBCAs. During this initial phase, it enhances blood vessels and areas with increased blood supply (the dynamic phase).

What makes Gadoxetate unique and highly effective for liver imaging is its hepatocyte-specific uptake. A significant portion of the injected dose (about 50%) is actively taken up by healthy liver cells (hepatocytes) via specific transporters (Organic Anion-Transporting Polypeptides, or OATPs). This active uptake allows for:

• Hepatobiliary Phase (HBP) Imaging: Approximately 10-20 minutes after injection (and sometimes up to 120 minutes), Gadoxetate concentrates within healthy liver cells. Most liver tumors, however, either lack these transporters or have dysfunctional ones, meaning they do not take up Gadoxetate. This causes tumors to appear as “dark spots” (hypointense) against a bright, enhanced background of healthy liver tissue, significantly improving their visibility and characterization.
• Differentiation of Lesions: This differential uptake helps distinguish various liver lesions. For example, some benign lesions (like focal nodular hyperplasia) may take up Gadoxetate and appear bright in the HBP, while many malignant tumors (like hepatocellular carcinoma or metastases) do not, appearing dark.

After uptake, Gadoxetate is excreted into the bile ducts by the liver cells, with the remaining portion eliminated by the kidneys.

• Gadoxetate shortens T1 relaxation time, making tissues appear brighter on MRI.
• It has a dynamic phase, enhancing blood vessels.
• Unique hepatobiliary phase: actively taken up by healthy liver cells via OATPs.
• Most liver tumors do not take up Gadoxetate, appearing dark against a bright liver.
• Aids in detecting and characterizing liver lesions and assessing liver function.
• Eliminated by both kidneys and liver (bile).

Like all medications, Gadoxetate can cause side effects. Most reactions are mild and temporary. However, it’s important to be aware of all potential side effects, including serious ones.

Common side effects often include:

• Headache.
• Nausea or vomiting.
• Feeling of warmth or coldness at the injection site.
• Dizziness.
• Back pain.
• Unusual taste in the mouth (dysgeusia).
• Injection site reactions: Pain, burning, swelling, or redness.

More serious, but less common, side effects that require immediate medical attention:

• Allergic (Hypersensitivity) Reactions: These can range from mild skin reactions (rash, hives, itching) to severe, life-threatening reactions (difficulty breathing, swelling of the face, lips, tongue, or throat, severe dizziness, chest pain, or collapse – anaphylaxis). These can occur immediately or, rarely, hours to days later.
• Nephrogenic Systemic Fibrosis (NSF): Gadoxetate is a linear GBCA and, like other linear agents, carries a significant warning regarding the risk of NSF in patients with severe kidney problems. NSF is a rare but very serious condition that causes hardening and thickening of the skin and other organs.
• Acute Kidney Injury: A sudden worsening of kidney function, especially in patients with pre-existing severe kidney disease.
• Seizures or convulsions.
• Cardiac issues: Chest pain, fast/slow/irregular heartbeat.
• Neurological symptoms: Confusion, changes in mental status, or agitation.

Report any new, unusual, or severe symptoms to the healthcare team immediately during or after your MRI scan.

Before administering Gadoxetate, your doctor and the imaging team will thoroughly evaluate your medical history and current health status, paying close attention to these critical warnings:

• Nephrogenic Systemic Fibrosis (NSF): This is the most significant warning for Gadoxetate. It is contraindicated (should not be used) in patients with:
  • Chronic, severe kidney disease (GFR < 30 mL/min/1.73m²).
  • Acute kidney injury. GBCAs like Gadoxetate increase the risk of NSF in these patient populations. Its use should be avoided unless the diagnostic information is essential and unavailable with non-contrast MRI or other methods. Patients at risk for reduced kidney function (e.g., over 60 years old, diabetes, hypertension) should have their kidney function tested (eGFR) before receiving Gadoxetate.
• Hypersensitivity Reactions: Inform the healthcare team if you have a history of allergies (including asthma or previous reactions to any contrast agents or medications). Severe allergic reactions, including anaphylaxis, can occur. Emergency equipment and trained personnel should be readily available. Observe patients for up to 2 hours post-administration.
• Not for Intrathecal Use: Gadoxetate is designed for intravenous injection only and must not be injected into the spinal canal (intrathecally). Intrathecal administration has caused serious and fatal neurological events.
• Gadolinium Retention: Gadolinium from GBCAs can be retained in various body tissues, including the brain, for prolonged periods. As a linear GBCA, Gadoxetate is associated with higher gadolinium retention than macrocyclic agents. The long-term clinical significance of this retention is still under investigation.
• Pregnancy and Breastfeeding: Inform your doctor if you are pregnant or planning to become pregnant. Gadoxetate should be used in pregnant women only if the potential benefit outweighs the potential risk to the fetus. For breastfeeding mothers, very small amounts pass into breast milk; your doctor may advise briefly stopping breastfeeding.
• Electrolyte Imbalance (Hypokalemia): Gadoxetate should be used with caution in patients with uncorrected low potassium levels (hypokalemia) due to potential effects on cardiac repolarization (QT prolongation), especially in patients with known risk factors for arrhythmias or on QT-prolonging drugs.

Gadoxetate generally has a low potential for direct drug-drug interactions through metabolic pathways, as it is primarily excreted unchanged by the kidneys and through liver/bile. However, there are some important considerations due to its unique hepatobiliary excretion:

• Drugs Affecting Liver Transporters: Medications that interfere with the Organic Anion-Transporting Polypeptides (OATPs) in the liver (which transport Gadoxetate into hepatocytes) could potentially affect the uptake and thus the enhancement pattern. Examples include some antibiotics (like rifampicin), antineoplastic agents, and certain antiviral drugs. This could reduce the contrast effect in the liver or alter its distribution.
• Bilirubin and Ferritin Levels: Elevated levels of bilirubin (a liver waste product) or ferritin (a protein storing iron) in the blood can reduce the liver’s uptake of Gadoxetate, potentially diminishing the contrast effect. Your doctor will consider these levels when planning your MRI.
• Kidney or Liver Impairment: While not direct drug interactions, conditions or medications that significantly impair kidney or liver function (especially severe liver disease with impaired OATP function) are important for your doctor to know. These conditions directly affect how Gadoxetate is eliminated and can influence its safety and efficacy.

It is crucial to inform your doctor, radiologist, and the healthcare team about all medications you are currently taking, including prescription drugs, over-the-counter medicines, herbal products, and supplements. This allows them to assess any potential risks or adjustments needed for your scan.

The dosage of Gadoxetate is precise and is determined by the healthcare professional based on the patient’s body weight and the specific MRI indication.

• Standard Dose (Adults and Pediatric Patients aged 2 months and older): The recommended dose is 0.025 mmol per kilogram (kg) of body weight. This corresponds to 0.1 mL of Gadoxetate solution per kg of body weight (since the solution is 0.25 mmol/mL).
• Administration: It is administered as a single intravenous injection, typically as a slow bolus or infusion, followed by a saline flush.
• Frequency: Gadoxetate is typically administered once for a single MRI examination. Due to the risk of gadolinium accumulation and NSF, repeat doses within a short interval (e.g., less than 7 days) are generally not recommended, especially in patients with kidney impairment. The lowest effective dose should always be used.
• Renal Impairment: For patients with severe renal impairment (GFR < 30 mL/min/1.73m²) or acute kidney injury, Gadoxetate is generally avoided unless absolutely essential. If used, the dose should not be exceeded, and careful monitoring is required. Hemodialysis can remove Gadoxetate from the body.

Always adhere to the specific dosage and administration instructions provided by your supervising medical team.

Gadoxetate (Eovist/Primovist) is a prescription-only medication (POM). It is never available over-the-counter in Pakistan or any other regulated healthcare system. Its strict prescription requirements are due to several crucial factors:

• Significant Risk of Nephrogenic Systemic Fibrosis (NSF): As a linear GBCA with a higher associated risk of NSF in vulnerable patients, strict medical oversight and patient screening (especially for kidney function) are mandatory.
• Intravenous Administration: It can only be administered by trained healthcare professionals in a controlled medical environment (hospital or imaging center).
• Specialized Diagnostic Use: Its unique hepatobiliary properties require specific expertise from radiologists and other imaging specialists for proper interpretation of the complex dynamic and hepatobiliary phase images.
• Patient Monitoring: Patients must be closely monitored during and after administration for potential adverse reactions.
• Regulatory Classification: As a gadolinium-based contrast agent, it falls under strict regulatory control globally.

Therefore, a licensed medical doctor, typically a radiologist or a liver specialist, must prescribe Gadoxetate. It will be administered to you in a hospital or an accredited diagnostic imaging center under strict medical supervision and established protocols. You will not receive this medication to take home.

What is Gadoxetate used for? Primarily for liver MRI to detect and characterize focal liver lesions

2. What is the active ingredient? Gadoxetate disodium

3. What drug class does it belong to? Gadolinium-based contrast agent (GBCA)

4. Is it a controlled substance? No

5. Is it available in generic form? No

6. How is it administered? Intravenous injection

7. What strengths are available? 0.25 mol/L solution (181.43 mg/mL)

8. What is the usual adult dosage? 0.1 mL/kg body weight (0.025 mmol/kg) IV

9. Can it be used in children? Approved for pediatric patients ≥2 years old

10. What are common side effects? Nausea, headache, dizziness, injection site reactions

11. Can it cause serious reactions? Yes—rare cases of nephrogenic systemic fibrosis (NSF), severe allergic reactions

12. Is it safe during pregnancy? Use only if benefits outweigh risks; gadolinium crosses placenta

13. Is a prescription required? Yes

14. Is Gadoxetate available in Pakistan? Not widely; may be accessed via radiology specialty import

15. How should it be stored? At 20–25°C; protect from light; do not freeze

16. What precautions should be taken during use? Assess kidney function before administration; monitor for hypersensitivity

17. What are contraindications? Severe renal impairment (risk of NSF), hypersensitivity to gadoxetate

18. What monitoring is needed during use? Renal function (eGFR), allergic reactions during and after injection

19. Can Gadoxetate be combined with other contrast agents? Not recommended; use single GBCA per imaging session

20. What are similar drugs? Gadobutrol (Gadavist), Gadobenate (MultiHance), Gadoterate (Dotarem), Gadoteridol (ProHance), Gadodiamide (Omniscan)